Nov 16 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc. and Adlai Nortye enter into $86.6
million regional licensing agreement for Reolysin
* Oncolytics Biotech Inc - Oncolytics to receive upfront,
licensing fee and milestone payments to support phase 3
registration study of usd $21.2 million
* Oncolytics Biotech - Co is eligible to receive up to
additional
$65.4 million upon achievement of clinical, regulatory,
commercialization milestones
* Oncolytics Biotech Inc - Upon Adlai Nortye's
commercialization
of reolysin, Oncolytics is eligible to receive double digit
royalty payments
* Oncolytics - Adlai to have exclusive development,
commercialization rights to Reolysin in China, Hong Kong, Macau,
Singapore, South Korea and Taiwan
Source text for Eikon: ID:nPn78H3mpa
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))